Press Releases

Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:

The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) published today four documents related to the pre-market regulatory oversight of a variety of biology-based agricultural tools, including genetically…

Delivers Message: India Must Protects Innovators’ Work Product

BIO's statement  regarding proposed drug pricing legislation within the Maryland Senate.

BIO announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to…

Washington, DC (December 7, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. Senate:

Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:

BIO responds to GAO's latest report on the Renewable Fuel Standard (RFS), “Renewable Fuel Standard, Program Unlikely to Meet its Targets for Reducing Greenhouse Gas Emissions.” GAO correctly concludes the technology is available for advance biofuels…

The Environmental Protection Agency’s final Renewable Fuel Standards for 2017 and biomass-based diesel volume for 2018 appear to put the program back on track and will provide considerable additional certainty for investors in advanced and…

BIO President and CEO Jim Greenwood released the following statement today regarding the FDA’s hearing on product communications:“In the era of data-driven medicine, where all parties seek more, not less, information about the safety,…